The Scan by 2 Minute Medicine®: FDA clears Alzheimer’s blood test, WHO warns of antibiotic resistance, New York confirms chikungunya case, and CDC layoffs raise concern

FDA approves Alzheimer’s blood test for use in primary care

The FDA just cleared a new blood diagnostic for Alzheimer’s developed by Roche and Lilly to help screen patients earlier in primary care. The Elecsys pTau181 assay measures phosphorylated tau-181 in plasma and reached a 97.9 % negative predictive value in trials. For many symptomatic patients, a negative result may allow clinicians to rule out Alzheimer’s with confidence. This is the first FDA clearance of a blood biomarker test indicated for primary care Alzheimer’s assessment. Previously, evaluation often required PET imaging or lumbar puncture. The approval may accelerate referrals, guide early patient counseling, and streamline trial enrollment. Still, the test does not replace cognitive exams or clinical context. Over the coming months, real-world performance, lab scalability, and reimbursement will determine its impact. Clinicians should prepare for interpreting biomarker results in everyday practice.

WHO warns one in six infections now antibiotic resistant

A recent WHO report estimates that one out of every six bacterial infections worldwide is now resistant to standard antibiotic therapies. The analysis draws from over 100 nations and documents resistance trends rising between 5 and 15 percent annually. Common pathogens such as E. coli and Klebsiella are particularly implicated, especially in urinary and bloodstream infections. In several regions, resistance rates now approach one in three for severe infections. WHO frames the rise as “a global emergency in slow motion,” warning that modern medicine’s most advanced interventions depend on effective antibiotics. Yet fewer than 30 new antibiotic agents are in late-stage development today. The report calls for expansion of diagnostics, antimicrobial stewardship, surveillance, and incentives for innovation. For physicians, the message is clear: localized antibiogram data and judicious prescribing are more important than ever.

New York confirms first locally acquired chikungunya case in six years

New York health authorities confirmed this week the first domestically transmitted chikungunya infection in the U.S. since 2019. The patient had no history of international travel, indicating local mosquito transmission within the state. Chikungunya typically produces fever, rash, and joint pain that can linger for months, though severe complications are rare. In response, vector surveillance and mosquito trapping were ramped up across affected boroughs. Experts point to expanding ranges of Aedes mosquitoes, driven by warming climates and urbanization, as a contributing factor. Global case totals in 2025 now exceed 440,000, with outbreaks spanning India, Brazil, and Southeast Asia. The CDC says localized transmission could soon become an annual phenomenon in temperate states. Arboviruses like chikungunya should now be included in differential diagnoses even when patients have no travel history. What once seemed tropical now feels uncomfortably local.

CDC layoffs raise alarm over surveillance and public health readiness

This week, the CDC issued layoff notices to around 1,300 employees, though hundreds of those notices have since been reversed. The departments impacted include immunization, epidemiology, and surveillance units. Some reinstatements suggest administrative error, but gaps remain in critical divisions. Critics warn that reduction of experienced staff during rising infectious disease activity is dangerously ill-timed. Congress is demanding oversight into how cuts could impede systems like FluView or outbreak reporting. For hospitals and clinicians, slower alerts or fewer guidance updates could become new constraints. Union leaders say public health knowledge is hard to rebuild once lost. The changes are unfolding amid a complex infectious disease landscape. Whether the restructuring strengthens or weakens long-term readiness remains to be seen.

Image: PD